Loading...
XNAS
RGEN
Market cap9.29bUSD
Dec 05, Last price  
164.98USD
1D
-0.47%
1Q
32.45%
Jan 2017
435.30%
Name

Repligen Corp

Chart & Performance

D1W1MN
XNAS:RGEN chart
P/E
P/S
14.64
EPS
Div Yield, %
Shrs. gr., 5y
2.60%
Rev. gr., 5y
18.61%
Revenues
634m
-0.68%
9,360,30912,911,40414,074,23919,296,28129,361,52120,971,06927,291,02462,266,53668,169,62363,548,34983,537,000104,541,000141,236,000194,032,000270,245,000366,260,000670,534,000801,536,000638,764,000634,439,000
Net income
-26m
L
-2,983,574696,860-889,26337,106,5145,746,028-4,063,844-43,50914,156,03716,093,1558,170,2149,345,00011,681,00028,353,00016,617,00021,411,00059,926,000128,291,000185,959,00041,577,000-25,514,000
CFO
175m
+53.97%
-795,277415,384405,48238,466,6016,307,144-2,448,3543,231,76313,439,60825,929,96718,401,29815,053,0007,521,00017,451,00032,770,00067,216,00062,625,000119,016,000172,083,000113,918,000175,394,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
IPO date
Apr 29, 1986
Employees
2,025
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT